A c-Met directed antibody-drug conjugate shows preliminary activity in a NSCLC cohort
Efficacy and safety of telisotuzumab adizutecan was investigated in patients with EGFR wild type non-squamous disease
Frontline abemaciclib plus endocrine therapy showed superior efficacy compared to chemotherapy in aggressive HR+/HER2– breast cancer
The combination therapy with the CDK 4/6 inhibitor improved overall response rate compared to standard treatment
Promising antitumour activity presented for emerging targets in different solid tumours
Strategies to target MTAP deletion, KRAS G12D and ESR1 mutations, and CDK4 and CDK2 further expand the landscape of precision oncology
Drug Rediscovery Protocol-like Clinical Trials facilitate access to precision oncology
Data from studies presented highlight the importance of integrating and incorporating comprehensive genomic profiling into clinical practice across a broad range of tumour types
Some clinical activity was reported for novel tyrosine kinase inhibitors in previously treated patients with GIST
However, the future of TKI combinations for these rare tumours is uncertain
Alectinib shows benefit across genetic profiles in resected ALK-positive NSCLC
New data from the ALINA study confirm lack of influence of EML4-ALK variant on outcome in this patient population
Regorafenib delays disease progression in patients with soft tissue sarcoma
Study findings indicate that the agent is promising as maintenance therapy, but managing its tolerability presents challenges
Clinical activity reported for novel first-line combination strategies in advanced triple-negative breast cancer
Early-phase clinical trial results show promise to optimise the current standard of care by using dual-targeting agents and investigating the most effective chemotherapy backbone for PD-L1 blockade
Claudin-targeted antibody–drug conjugates are promising treatments for solid tumours
According to results from several phase I trials, this precision oncology strategy also offers manageable safety
Questions still remain on optimal adjuvant therapy in advanced melanoma
Overall survival benefits of systemic therapy in the adjuvant setting are still unclear in clinical trials, and may need to be complemented with real-world studies